New restrictions on functional claims for complementary medicines in Australia
Following a 17 month process of consultation and legislative policy formation, the Therapeutic Goods Amendment (2017 Measures No. 1) Act 2018 (Cth) was assented to. This federal law reform will result in a list of permitted claims used in marketing functionality of a therapeutic product. The proposed list of claims is called the Low Level Indications List. This article elaborates on these reform laws and the implications.